Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
Type
Guidance (373)
NICE advice (1)
Quality standard (8)
Guidance programme
Guidance programme
Clinical guidelines (25)
Diagnostics guidance (6)
Health technology evaluations (14)
Highly specialised technologies guidance (5)
Interventional procedures guidance (15)
Medical technologies guidance (8)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (300)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 161 to 170 of 382
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]
Technology appraisal guidance
TBC
Insulin icodec for treating type 2 diabetes [ID6175]
Technology appraisal guidance
TBC
Intrapartum Care - Water birth: second stage of labour
NICE guideline
14 November 2025
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy ID6556
Technology appraisal guidance
28 October 2026
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
Technology appraisal guidance
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Technology appraisal guidance
TBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]
Technology appraisal guidance
TBC
Iptacopan for treating complement 3 glomerulopathy [ID6283]
Technology appraisal guidance
8 January 2026
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3981]
Technology appraisal guidance
10 September 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]
Technology appraisal guidance
TBC
Previous page
1
…
15
16
Current page
17
18
19
…
39
Page
17
of
39
Next page
Results per page
10
25
50
All
Back to top